Capital Bluecross genetic testing coverage update

Coverage Criteria for Genetic Testing

Long QT Syndrome (LQTS) - Covered indications

Genetic testing for LQTS is considered medically necessary when any of the following conditions are met:

LQTS diagnostic and familial testing: 1) Genetic testing to confirm congenital LQTS when signs and/or symptoms are present but a definitive diagnosis cannot be made without genetic testing (includes individuals with Schwartz score <4 but moderate-to-high pretest probability); OR 2) Genetic testing of asymptomatic individuals when a close relative (first-, second-, or third-degree) has a known LQTS variant; OR 3) Genetic testing of asymptomatic individuals when a close relative is clinically diagnosed with LQTS and genetic status is unavailable.

Genetic testing for other situations (including determining prognosis or directing therapy in known LQTS) is investigational.

Brugada Syndrome (BrS) - Covered indications

Genetic testing for BrS is considered medically necessary when either of the following conditions are met:

BrS diagnostic and familial testing: 1) Genetic testing to confirm BrS when signs and/or symptoms consistent with BrS are present but a definitive diagnosis cannot be made without genetic testing; OR 2) Genetic testing of asymptomatic individuals when a close relative (first-, second-, or third-degree) has a known BrS variant.

All other situations are investigational.

Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) - Covered indications

Genetic testing for CPVT is considered medically necessary when either of the following conditions are met:

CPVT diagnostic and familial testing: 1) Genetic testing to confirm CPVT when signs and/or symptoms are present but a definitive diagnosis cannot be made without genetic testing; OR 2) Genetic testing of asymptomatic individuals when a close relative (first-, second-, or third-degree) has a known CPVT variant or when a close relative is clinically diagnosed with CPVT and genetic status is unavailable.

All other situations are investigational.

Short QT Syndrome (SQTS) - Covered indications

Genetic testing for SQTS of asymptomatic individuals is considered medically necessary when:

SQTS familial testing: An asymptomatic individual has a close relative (first-, second-, or third-degree) with a known SQTS variant.

Other indications are investigational.

LQTS: Covered when clinically suspected or for relatives of known carriers

Long QT Syndrome

LQTS_diagnostic_and_familial: Genetic testing for LQTS is considered medically useful when there is suspected congenital LQTS with moderate-to-high pretest probability, and for asymptomatic close relatives of a proband with a known pathogenic familial LQTS variant.variant identified in ~70% of clinically diagnosed LQTS; targeted family testing definitive if familial variant known

Testing leads to treatment (β-blockers, sometimes ICD) and is sufficient to improve net health outcome

Brugada Syndrome: Conditional coverage for symptomatic patients and relatives of known variant carriers

Brugada Syndrome

BrS_symptomatic_or_familial: Genetic testing for BrS has low clinical validity (15%-35% yield) but is considered medically necessary to establish a definitive diagnosis in symptomatic patients and to evaluate family members of an individual with a known BrS pathogenic variant; its utility in asymptomatic individuals without a known familial variant is limited.SCN5A accounts for >20% of cases; overall >65% have no identified genetic cause

Guidelines and clinical input support testing despite limited evidence

CPVT: Covered for probands and relatives

Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

CPVT_diagnostic_and_familial: Genetic testing for CPVT is considered medically useful for individuals with suspected CPVT and for asymptomatic close relatives of patients with known pathogenic variants, given a ~55%-65% variant detection rate and clear impact on management to reduce arrhythmia and SCD risk.RYR2 variants represent 50%-55% of cases; penetrance ~83%

Testing leads to preventive treatment in variant-positive relatives

SQTS: Limited coverage — familial testing supported

Short QT Syndrome (SQTS)

SQTS_symptomatic_or_familial: Genetic testing for SQTS has limited and not well-characterized yield; evidence is insufficient to determine benefit for symptomatic probands without other definitive signs, but testing may be useful for asymptomatic family members of individuals with a known pathogenic SQTS variant when results would affect management.Most linked to KCNH2, KCNJ2, KCNQ1; inheritance often autosomal dominant

Clinical input lacked consensus for symptomatic testing but supported familial predictive testing

Covered with criteria / Considered positions

Policy statements and evidence synopsis present the following positions

Genetic testing may be considered: Testing may be considered for asymptomatic family members of individuals with known SQTS variants or when a cardiologist has a strong clinical index of suspicion for SQTS.

Evidence is limited; testing for SQTS discussed in guidelines; generally used when specific diagnosis suspected.

Testing after specific diagnosis suspected: In studies of asymptomatic individuals with a close family member who experienced sudden cardiac death, genetic testing was performed only after a specific diagnosis was suspected based on history or ancillary testing.

Evidence insufficient to determine effects on health outcomes.

Genetic testing for congenital LQTS: Genetic testing in members with a diagnosis of congenital long QT syndrome may be considered medically necessary when results will be used to guide medical management.

Policy history notes addition of this statement (02/08/2023).

Genetic testing for cardiac ion channelopathies (LQTS, BrS, CPVT, SQTS) that does not meet the specific diagnostic or familial criteria listed for each disorder is considered investigational. Examples include testing performed solely to determine prognosis or to direct therapy in individuals with a known diagnosis when the formal criteria are not met. There is insufficient evidence to conclude that such testing improves health outcomes for these non-specified indications.

For Short QT Syndrome (SQTS), the evidence is limited and testing yields are not well characterized. Genetic testing in symptomatic individuals who lack a definitive clinical diagnosis has insufficient evidence to demonstrate benefit because it is unclear that identifying a variant without other clinical signs leads to management changes that improve outcomes.

There are scenarios in which the evidence does not permit a determination of clinical benefit from genetic testing. In such cases coverage decisions are subject to member benefit limitations and medical necessity determinations. Providers should verify eligibility and benefits and understand that code identification does not guarantee coverage.

Genetic testing performed outside the disorder-specific criteria listed in this policy is considered investigational. Testing outside the listed clinical or familial indications lacks sufficient evidence of benefit and may be denied.

The clinical utility of genetic testing for SQTS in symptomatic probands is uncertain. Available data provide limited information on testing yield and there is no clear evidence that a genetic diagnosis in the absence of other clinical signs changes management in a way that improves outcomes; specialty input reflected lack of consensus for symptomatic testing.

Genetic testing in asymptomatic individuals whose family members experienced arrhythmic events or sudden cardiac death has insufficient evidence to determine effects on health outcomes when testing is not preceded by a suspected specific diagnosis. Testing in these scenarios may be considered only when results would meaningfully affect management and per member benefits.

Coding and Diagnostic Criteria

Covered when medically necessary / Procedure and molecular codesmixed

81414	Procedure Codes (listed as covered when medically necessary)
81401	Procedure Code referenced in coding list
81403	Procedure Code referenced in coding list
81404	Procedure Code referenced in coding list
81405	Procedure Code referenced in coding list
81406	Procedure Code referenced in coding list
81407	Procedure Code referenced in coding list
81408	Procedure Code referenced in coding list
81413	Procedure Code referenced in coding list
0237U	Molecular pathology code (listed in coding list)

Covered when medically necessary / Diagnosis and screening codesmixed

I45.81	Long QT syndrome
I47.21	Torsades de pointes
I47.29	Other ventricular tachycardia
I49.8	Other specified cardiac arrhythmias
I49.9	Cardiac arrhythmia, unspecified
Z13.6	Encounter for screening for cardiovascular disorders
Z13.79	Encounter for other screening for genetic and chromosomal anomalies
Z13.89	Encounter for screening for other disorder

Short QT cutoff (QTc)

Short QTc cutoff (men)QTc < 350 ms

Short QTc cutoff (women)QTc < 360 ms

SQTS definition relative to populationQTc < 2 standard deviations below the mean

Provider Actions, Documentation, and Testing Strategy

Documentation Required

Prior Evaluation Required (Documentation)

Prior to ordering genetic testing for cardiac ion channelopathies, a comprehensive clinical evaluation is required. This evaluation should include documentation of the individual’s personal and family history, physical examination, 12‑lead electrocardiogram, and other cardiac testing as clinically indicated (e.g., exercise stress test, transthoracic echocardiography, advanced cardiac imaging, or electrophysiologic testing). Testing should be considered only when, after completion of this comprehensive evaluation, there remains a moderate‑to‑high pretest probability of an inherited channelopathy (LQTS, CPVT, BrS) or when a known familial pathogenic/likely pathogenic variant exists.

Required documentation: history (including circumstances of any sudden cardiac arrest/death), physical exam, 12‑lead ECG, and results of other cardiac studies used to reach the decision to test.
If a familial pathogenic/likely pathogenic variant is known, testing should begin by targeted testing for that known variant.
When a family member’s genetic diagnosis is unavailable, single‑gene or panel testing may be considered following the comprehensive clinical evaluation.
Genetic testing may be part of the diagnostic workup for survivors of sudden cardiac arrest or relatives of unexplained sudden cardiac death only after the recommended post‑event and clinical evaluations have been completed.

Background on Cardiac Ion Channelopathies

Cardiac ion channelopathies are inherited disorders caused by variants in genes that encode cardiac ion channel subunits and related proteins. These disorders — including Long QT Syndrome (LQTS), Brugada Syndrome (BrS), Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), and Short QT Syndrome (SQTS) — alter cardiac action potentials and increase risk of ventricular arrhythmias and sudden cardiac arrest or death. Accurate diagnosis is critical because management (for example, β-blockers or implantable cardioverter-defibrillators in LQTS and targeted preventive measures in CPVT) depends on distinguishing these primary electrical disorders from other causes of arrhythmia.

Definitions and Diagnostic Terms

Cardiac ion channelopathies — definition

DefinitionDisorders resulting from variants in genes that code for protein subunits of the cardiac ion channels that alter ion flow and cardiac action potentials, associated with ventricular arrhythmias and increased risk of sudden cardiac death.

Clinical significanceCan be difficult to diagnose; incorrect diagnosis may be catastrophic due to risk of ventricular arrhythmias and SCD.

Examples included in policyLong QT syndrome (LQTS), Brugada syndrome (BrS), catecholaminergic polymorphic ventricular tachycardia (CPVT), and short QT syndrome (SQTS).

SCA / SCD definition

DefinitionSudden cardiac arrest (SCA) or sudden cardiac death (SCD) refers to the sudden interruption of cardiac activity with circulatory collapse.

Common cause

OpenPayer

Genetic Testing for Cardiac Ion Channelopathies

Coverage Criteria for Genetic Testing

Coding and Diagnostic Criteria

Provider Actions, Documentation, and Testing Strategy

Background on Cardiac Ion Channelopathies

Definitions and Diagnostic Terms

Revision History and Policy Updates